Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)for Acute Myeloid Leukemia211 locations incl. BirminghamSponsor: National Cancer Institute (NCI)Sex: All·Age: 18 - 59Code: NCT05554406·Phase 2·RecruitingApply to this trial
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)for Recurrent Lung Non-Small Cell Carcinoma266 locations incl. DaphneSponsor: SWOG Cancer Research NetworkSex: All·Age: 18 Minutes+Code: NCT06031688·Phase 2·RecruitingApply to this trial
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Studyfor Metastatic Colorectal Adenocarcinoma185 locations incl. KingmanSponsor: Alliance for Clinical Trials in OncologySex: All·Age: 18+Code: NCT05673148·Phase 3·RecruitingApply to this trial
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)for Acute Myeloid LeukemiaDrug: Venetoclax167 locations incl. BirminghamSponsor: National Cancer Institute (NCI)Sex: All·Age: 18 - 59Code: NCT05554393·Phase 2·RecruitingApply to this trial
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistulafor Pancreatic Carcinoma118 locations incl. La JollaSponsor: SWOG Cancer Research NetworkSex: All·Age: 18+Code: NCT06807437·Phase 3·RecruitingApply to this trial
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)for Lung Non-Small Cell Carcinoma248 locations incl. JonesboroSponsor: SWOG Cancer Research NetworkSex: All·Age: 18+Code: NCT06116682·Phase 2·RecruitingApply to this trial
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphomafor Diffuse Large B-Cell Lymphoma87 locations incl. TucsonSponsor: SWOG Cancer Research NetworkSex: All·Age: 18+Code: NCT05633615·Phase 2·RecruitingApply to this trial
Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancerfor Advanced Clear Cell Renal Cell Carcinoma41 locations incl. FayettevilleSponsor: SWOG Cancer Research NetworkSex: All·Age: 18+Code: NCT07383441·Phase 3·RecruitingApply to this trial
Collection and Storage of Tissue and Blood Samples From Patients With Cancerfor Hematopoietic and Lymphatic System Neoplasm140 locations incl. Fort SmithSponsor: National Cancer Institute LAOSex: All·Age: 2 Months+Code: NCT02474160·RecruitingApply to this trial
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosisfor AL Amyloidosis117 locations incl. GoodyearSponsor: SWOG Cancer Research NetworkSex: All·Age: 18+Code: NCT06022939·Phase 3·RecruitingApply to this trial
Education & Mentorship of Advanced Practice Providers to Increase Community-based Research Within the NCORP Network, COACH-APP Trialfor Other31 locations incl. NewarkSponsor: Wake Forest University Health SciencesSex: All·Age: 18+·Accepts healthy volunteersCode: NCT06904391·RecruitingApply to this trial
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatmentfor Lung Non-Small Cell Carcinoma33 locations incl. JonesboroSponsor: Alliance for Clinical Trials in OncologySex: All·Age: 18+Code: NCT07293247·Phase 2·RecruitingApply to this trial
Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)for Core Binding Factor Acute Myeloid LeukemiaDrug: Venetoclax23 locations incl. Coeur d'AleneSponsor: National Cancer Institute (NCI)Sex: All·Age: 18 - 59Code: NCT06917911·Phase 2·RecruitingApply to this trial
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trialfor Anatomic Stage II Breast Cancer AJCC v8Drug: Ribociclib61 locations incl. JonesboroSponsor: National Cancer Institute (NCI)Sex: All·Age: 18+Code: NCT07391774·Phase 3·RecruitingApply to this trial